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articLe addenduM
Clostridium difficile is a major cause of antibiotic associated 
diarrhea. Recently, we have shown that 
effective protection can be mediated 
in hamsters through the inclusion 
of specific recombinant fragments 
from toxin A and B in a systemically 
delivered vaccine. Interestingly while 
neutralizing antibodies to the binding 
domains of both toxin A and B are 
moderately protective, enhanced survival 
is observed when fragments from the 
glucosyltransferase region of toxin B 
replace those from the binding domain of 
this toxin. In this addendum, we discuss 
additional information that has been 
derived from such vaccination studies. 
This includes observations on efficacy 
and cross-protection against different 
ribotypes mediated by these vaccines and 
the challenges that remain for a vaccine 
which prevents clinical symptoms but 
not colonization. The use and value of 
vaccination both in the prevention of 
infection and for treatment of disease 
relapse will be discussed.
Introduction
Clostridium difficile is a leading cause 
of antibiotic associated diarrhea and 
susceptibility to this infection increases 
with age, immunodeficiency, and 
antibiotic treatment1. While carriage 
of the organism within the gut can 
be asymptomatic, modification of the 
flora through antibiotic use frequently 
initiates disease. Symptoms ranging 
from mild to severe diarrhea are largely 
associated with the production of two 
large glucosyltransferase exotoxins, TcdA 
and TcdB2, which modify and damage 
the cellular architecture of the epithelial 
surface of the colon. This damage not 
only limits absorption of water but 
also induces through inflammasome 
activation a prolific inflammatory 
response including an influx of high 
numbers of polymorphonucleocytes 
(PMNs). While symptoms can be 
alleviated through the destruction and 
removal of the toxin-producing bacteria 
through treatment with metronidazole 
or vancomycin, further complications 
including pseudomembranous colitis, 
toxic megacolon, and sepsis also occur in a 
small number of cases3.
Animal Models
The efficacy of any new treatment 
for C. difficile requires early evaluation 
in appropriate animal models. Until 
recently, the “gold standard” model for 
C. difficile infection was considered to 
be the Syrian Golden hamster. Unlike 
mice, the challenge of clindamycin treated 
animals with spores or vegetative cells 
results in an acute and fatal outcome with 
many symptoms including diarrhea and 
inflammation of the colon (including 
damage resembling pseudomembranous 
eruptions) similar to those observed in 
man. In contrast, genetically normal mice 
only appear to be transiently colonized 
when experimentally infected, with little 
Vaccination against Clostridium difficile using toxin fragments
Observations and analysis in animal models
Janice Spencer1, Rosanna Leuzzi2, Anthony Buckley1, June Irvine1, Denise Candlish1, Maria Scarselli2, and Gillian R Douce1,*
1Institute of Infection, Immunity, and Inflammation; College of Medicine, Veterinary and Life Sciences; University of Glasgow; Glasgow, UK;  
2Novartis Vaccines and Diagnostics; Siena, Italy
Keywords: Clostridium difficile, 
vaccination, toxin fragments, neutralizing 
antibodies, hamster models, diarrhea, 
colonization factors, glucosyltransferase 
activity, protection
*Correspondience to: Gillian R Douce;  
Email: Gillian.Douce@glasgow.ac.uk
Submitted: 09/20/2013
Revised: 12/08/2013
Accepted: 01/02/2014
Published Online: 01/22/2014
http://dx.doi.org/10.4161/gmic.27712
Addendum to: Leuzzi R, Spencer J, Buckley A, 
Brettoni C, Martinelli M, Tulli L, Marchi S, Luzzi 
E, Irvine J, Candlish D, et al. Protective efficacy 
induced by recombinant Clostridium difficile 
toxin fragments. Infect Immun 2013; 81:2851-
60; PMID:23716610; http://dx.doi.org/10.1128/
IAI.01341-12
226 Gut Microbes Volume 5 issue 2
or no changes in tissue pathology observed. 
However, work by Chen4 demonstrated 
that pre-treatment of mice with a 
combination of antibiotics in the drinking 
water modifies the microbiota such that 
subsequent exposure to clindamycin and 
C. difficile spores results in significant 
tissue pathology and in some cases death. 
Disease severity can be measured indirectly 
by monitoring mouse weight, which drops 
significantly 2 days post infection. This 
weight loss appears transient with recovery 
to normal weight observed 4 days post 
infection. A less severe but useful mouse 
model is the “transmission model” which 
models spread of this infection between 
susceptible individuals. In this model, 
mice infected with C. difficile transiently 
shed high levels of the organism within 
the feces. Approximately 1 week post 
challenge, infection appears cleared as 
recovery of detectable bacteria in the feces 
is difficult. However, the organism appears 
to be retained at low levels as subsequent 
treatment with clindamycin and/or 
vancomycin provokes the outgrowth, with 
C. difficile being readily detected in the 
faces. Under certain circumstances, some 
animals develop “supershedder” status, 
continually secreting high levels of spores 
within the feces. This model has been 
very elegantly used to evaluate the role of 
the microbiota in disease and the fitness 
of particular ribotypes to dominate this 
niche in vivo5.
C. difficile infects a wide range of 
animals and is one of the major causes of 
enteritis in neonatal pigs. Oral infection 
of such pigs experimentally with toxin-
producing strains results in severe 
inflammation within the large bowel. 
Interestingly modification of the dose 
and age of the pig can influence both the 
severity (from acute and severe disease) 
and type (mild vs. chronic) disease6. 
While housing and cost has limited 
widespread use of the model, the recently 
discovered overlap in strains recovered 
from man and pigs suggests that these 
animals may provide the ultimate model 
for this disease. If pigs provide a reservoir 
of infection for this pathogen, then 
development of a swine vaccine may be 
appropriate as we look to reduce and/or 
eliminate the bacterial burden of infection 
within the environment.
Vaccination to Prevent C. difficile
While current treatments for 
symptomatic disease are based upon the 
administration of additional antibiotics, 
frequent recurrence of disease following 
withdrawal of treatment has strengthened 
the need for alternative approaches. 
Vaccination using toxoids or recombinant 
fragments has been tested in both animals 
and man with varying and limited success. 
Protection appears dependent on the 
production of high levels of neutralizing 
antibody to both toxin A and toxin B. 
In fact, passive transfer of monoclonal 
antibodies to these toxins provides 
protection against C. difficile in human 
subjects7. In man, the presence of high 
levels of systemic toxin A antibodies alone 
appears to correlate with protection from 
Clostridium difficile associated diarrhea 
(CDAD) 8. In contrast, there is some 
evidence that the level of neutralizing 
antibodies to toxin B correlates with the 
prevention of disease and relapse9,10. While 
protection has largely been attributed to 
neutralizing antibodies generated to the 
binding domains of these toxins, recent 
work by this group and confirmed by 
others11 has indicated that high titers of 
neutralizing antibodies to toxin B can be 
generated using regions other than the 
binding domain. These antibodies appear 
to provide greater protection in animal 
models as well as reducing the longevity 
and severity of diarrheal symptoms 
associated with this disease.
Protective Efficacy 
 of Toxin Repetitive Binding 
Domains (RBD)
Early studies in animals and more 
recent clinical studies in man have 
focused on the use of detoxified versions 
of the proteins to generate protective 
immunity12-16. A summary of such vaccines 
is given in Table 1. However, difficulties 
in the manufacture and efficacy of 
the toxoid based vaccines including 
variation in the quantity and quality 
of neutralizing antibodies generated 
suggest an opportunity for improvement. 
Several groups have considered the use 
of recombinant antigens based on the 
repetitive binding domains (RBD) located 
at the C terminus of both toxins17-19. X-ray 
structural analysis of this region in TcdA 
revealed that these sequences fold into 
repetitive solenoid-like structures20 that 
have potential as vaccine candidates. This 
was first demonstrated in the 1990s by 
Lyerly, who showed that a recombinant 
protein encoding 33 of the 38 regions 
of toxin A were sufficient to protect 
animals against toxin A challenge21. 
These fragments generated neutralizing 
antibodies which appeared essential 
in prevention of lethality in the Syrian 
Golden hamster model of infection. Over 
the intervening years, several formulations 
of experimental vaccines have been tested 
using different routes of immunisation 
and delivery vehicles to enhance immune 
responses22-25 (Table 1). More recently, 
groups18,19 have revised the formulation 
to include toxin B, as fragments of toxin 
A alone failed to provide full protection. 
This has shown that systemic vaccination 
of RBDs of both toxins can prevent lethal 
disease.
Most of the RBD fragments used in such 
studies have been cloned using genomic 
sequences from two strains of C. difficile, 
the highly toxic strain VPI10463 or 630 
from which the first annotated sequence 
was generated26.While these fragments 
generate strong neutralizing antibodies, 
documented variation in the toxin B RBD 
may limit the potential of these antigens 
to completely neutralize the activity of 
variant toxins. Using RBD fragments 
of toxin A (2387–2710 nt) and toxin B 
(1853–2366 nt) cloned from 630, we have 
shown varying degrees of protection in the 
hamster model using 3 different strains of 
C. difficile (Fig. 1). These differences may 
reflect either variation in the neutralizing 
capacity of the antibody to divergent 
toxins or differences in the amount and 
activity of the toxins produced in vivo. In 
our hands and confirmed in observations 
by others27 630 appears to generate less 
toxin over an equivalent time period than 
C. difficile strains B1 or R20291.
Variation in the amount of antigen 
used in vaccination has been shown to 
influence the level of protection with 
animals vaccinated with a reduced 
formulation (30 μg per dose of RBDs from 
TcdA and TcdB) being more susceptible 
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Table 1. Summary of vaccines formulations against C. difficile described in the literature
Toxoids preparations Animal model/clinical study Route of immunization References
toxoid a and B from culture filtrates Hamster parenteral (i.p., s.c.) + mucosal (i.n., i.g., r.) 13
partially purified toxoid a and B Hamster parenteral (i.m.) + mucosal (i.n., i.g., r.) 12
partially purified toxoid a and B Healthy adults 4 doses i.m. 14, 44
partially purified toxoid a and B
purified toxoid B
patients
Hamster
4 doses i.m
3 doses i.p
45
16
Highly purified toxoid a and B (> 90%) Hamster i.m. 46
Highly purified toxoid a and B (> 90%) Healthy adults, elderly 3 doses i.m 15
Genetically modified toxoid a and B Hamster i.m. 47
Recombinant toxin-based antigens
rBd tcda Hamster subcutaneous 21
rBd tcda rabbit Oral/V. cholerae vector 22
rBd tcda Mice i.n., i.g. 17
rBd tcda/B Mice, hamster i.g./B. subtilis spores 24
rBd tcda Mice dna vaccine, i.m. 23
rBd tcda Mice adenovirus vaccine, i.m. 25
Fusion protein rBds of tcda/B Mice, hamster, monkey i.m. 18
toxina/B chimeric protein Mice, hamster i.m., i.p. 11
rBds and Gt of tcda/B Mice, hamster i.p. 19
Surface antigens
crude SLp Mice, hamster i.p., i.n. 34
Flid Mice i.n., r., i.g./ pLGa encapsulation 35
cwp84 Hamster s.c., r., i.g 36
cwp84 Hamster i.g./ pectin beads encapsulation 37
i.p. = intraperitoneal, s.c. = subcutaneous, i.n. = intranasal, i.g. = intragastric, r. = rectal, i.m. = intramuscular
Figure 1. Survival of clindamycin  treated vaccinated hamsters challenged with C. difficile. (A) shows the survival of animals following vaccination with 
rBd-tcda630 and rBd-tcdB630 (50 μg per dose and/or 4 vaccinations) and challenged with C. difficile 630 (closed circles), B1 (closed square), and r20291 
(closed triangles). unvaccinated controls for each strain are also included (closed diamonds). (B) shows the survival time of animals vaccinated with 4 
doses of either rBd-tcda630 and rBd-tcdB630 (open squares) or rBd-tcda630 and tcdB-Gt630 open circles) 30 μg per dose and challenged with C. difficile 
B1. unvaccinated controls for each strain are also included (open triangles). each experiment represents a minimum of 6 animals per group. differences 
in survival for animals immunized with rBd-tcda630 and rBd-tcdB630 between (A) and (B) may reflect the impact of a lower dose of proteins given to 
animals challenged with C. difficile B1 in (B).
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to fatal disease (Fig. 1B). This appears 
particularly true for the RBD from toxin 
B, which in general seems to be less 
immunogenic than the equivalent toxin 
A protein. Whilst high titers of antibodies 
to toxin A have been observed after single 
vaccinations, several vaccinations are 
required to generate even the most limited 
anti toxin B response13.
Identification of Alternative  
and Effective Neutralising 
Epitopes for Toxin B
In the last decade the number 
and complexity of C. difficile cases 
have increased worldwide and while a 
proportion of these cases can be attributed 
to increased vigilance, the emergence 
and spread globally of a number of 
hypervirulent and epidemic strains has 
also contributed. In the UK, the progenitor 
of the epidemic 027 ribotype (known as 
R20291 or UK1) was isolated in 2006 at 
Stoke Mandeville during an outbreak that 
resulted in over 30 deaths. The spread 
and evolution of this strain worldwide has 
recently been documented28, although a 
conclusive explanation for its rapid spread 
and dominance remains elusive. However, 
it is clear that vaccines of the future need 
to show clear efficacy against such strains. 
While the use of a TcdB toxoid appears to 
generate immunity that is cross protective 
between phylogenetically distinct 
C. difficile strains16 , the RBD region of 
this toxin has been reported to be variable 
between different toxinotypes2,29,30. We 
and others11 have considered the use of 
other more conserved regions of the toxin 
as vaccine candidates. More specifically, 
we have shown that a recombinant 
fragment encoding the glucosyltransferase 
activity of toxin B (TcdB-GT 1–543 nt) 
in combination with the RBD region of 
toxin A can raise neutralizing antibodies. 
This fragment appears to generate superior 
protective responses to the equivalent RBD 
of toxin B when used in combination with 
RBD from toxin A in parallel experiments 
(Fig. 1B). Inclusion of this region has 
also been shown in the mouse model of 
relapsing disease to reduce recurrence 
of the disease. This result provides an 
argument for inclusion of these domains 
in future superior vaccines. The potential 
of the catalytic domain as a source of 
toxin B neutralizing epitopes has further 
been confirmed through the creation of 
a chimeric protein in which the RBD of 
toxin B was exchanged for the equivalent 
RBD from toxin A11.
Protection from Local  
or Systemic Toxic Activity
While activity of the toxin at the 
mucosal barrier is well documented, the 
systemic impact of toxin action is less 
clear. Hamsters, unlike mice, appear 
acutely sensitive to the toxins, with 
animals succumbing to an acute lethal 
disease between 24–48 h following oral 
challenge. These animals do not appear 
to die as a consequence of dehydration 
attributed to diarrhea as animals that 
show intermediate levels of protection 
suffer several episodes of diarrhea followed 
by recovery. In contrast, naive infected 
animals develop diarrhea and rapidly 
become moribund. Data from zebrafish31, 
and more recently from gnotobiotic 
piglets10, have highlighted the sensitivity of 
cardio and pulmonary tissue to C. difficile 
toxins. While no gross pathology has been 
observed in these tissues in hamsters, our 
current use of biotelemetry has indicated a 
role for these toxins systemically. Animals 
with acute infection show a short rise in 
body temperature followed by a rapid 
and sustained reduction that is associated 
with organ failure (Fig. 2). In contrast, 
vaccinated animals show a small but 
sustained elevation at the same time as the 
naive animals before a return to normal 
biorhythms. This elevation in temperature 
may reflect the release of cytokines such as 
interleukin 1β (IL-1β) 32, which have been 
shown to be released from macrophages 
exposed to either TcdA or TcdB. This 
cytokine together with IL-6 has been 
shown to be higher in pigs and mice with 
systemic CDI and may be responsible 
for the increase in body temperature 
observed33. Neutralization of toxins as 
a consequence of vaccination may limit 
inflammatory cytokine release and alter 
the subsequent downstream effects which 
in the hamsters are lethal. At present, it 
is unclear whether systemic toxicity has 
a role clinically, and it will be difficult 
to determine given that the majority of 
Figure 2. Body temperature fluctuations in naive and vaccinated hamsters infected with C. difficile. (A) represents the typical change in temperature 
observed in a naive animal (red line) and a vaccinated animal (black line) during the same stage of infection. readings are taken every minute from an 
implanted chip within the infected animal. (B) represents the typical profile of temperature variation in a vaccinated and protected animal during a 14 
day experiment. the red bar represents the time over which diarrhea was observed. (C) represents the profile observed in partially protected animals, 
which display intermittent episodes of diarrhea and recovery.
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infections occur in elderly hospitalized 
patients with complicated medical 
histories. However, it may be speculated 
that these toxins contribute indirectly to 
organ failures in these weakened patients. 
These observations further support the 
use and development of vaccines against 
the toxins.
Protection from Toxin Mediated 
Symptoms but Not Colonization
Systemic vaccination with C. difficile 
toxoid vaccines have been shown to 
generate high levels of serum antibodies 
that appear to reduce the potential for 
relapse. The difficulty with this approach is 
the availability of strong toxin-neutralizing 
activity at the epithelial barrier. In 
systemically vaccinated and protected 
animals, short and self-limiting episodes 
of diarrhea are frequently observed11,14. 
It has been suggested that this reflects 
damage to the gut epithelium, initiated 
by early toxin production, which releases 
toxin neutralizing antibodies from the 
local vasculature of the gut. Early studies, 
in which mucosal vs. systemic vaccinations 
were compared, indicated that only the 
production of mucosal responses through 
a combination of systemic and mucosal 
immunization limited these symptoms13. 
In our hands mucosal vaccination alone 
with recombinant fragments of receptor 
binding domains elongates survival time 
(by approx 10 h) but does not prevent the 
eventual systemic impact of the toxin (data 
not shown). This suggests that strategies 
that activate both mucosal and systemic 
responses would be optimal for complete 
prevention of symptoms.
However, is prevention of symptoms 
sufficient? In our hands, vaccinated 
animals that show limited or no diarrheal 
symptoms continue to shed the organism 
at high levels in the feces for up to 3 weeks 
post infection (Fig. 3A). This would 
suggest that while vaccination prevents 
Figure 3. Bacteria in the feces in vaccinated animals challenged with three toxic strains (630, B1, or r20291) or naive animals infected with naturally 
non-toxic strain of C. difficile. (A) shows the recovery of C. difficile (cfu per 100 mg feces) over time in vaccinated animals following challenge with strains 
630 (red), B1 (green), r20291 (purple) and naive animals infected with paLoc negative strain 1342 (black). error bars represent the standard error of the 
mean cfu counts from a minimum of 6 animals per strain. * indicates time points at which spores were not recovered and $ time point at which no feces 
were recoverable due to diarrheal episode. (B). immunofluorescence of paLoc negative strain 1342 in cecal tissue 1 day post infection. 3b (i) shows low 
power magnification of infected tissue in which C. difficile are stained with anti-surface layer protein a (slpa) antibodies. images are observed at 490 
nm (green fluorescent protein, gfp highlighting tissue) and 580nm (red fluorescent protein (rfp), highlighting C. difficile). 3b (ii) is identical image from 
(i) using the 580nm filter alone. 3b (iii) shows magnification of highlighted region from 3b (i) using 490 and 580 filter sets. 3b (iv) is the image from (iii) 
using the 580nm filter alone. images were prepared from formaldehyde fixed tissue. de-waxed sections were stained with anti-rabbit slpa antibody 
(1:1000; 90 min; 37 °c) and counterstained with goat anti rabbit igG conjugated with alexa Flior 555 (Life technologies; 1:1000; 90 min; 37 °c). Stained 
slides were visualized using a Zeiss imager M1 microscope with images taken using a Hamamastsu Orca-er digital camera and improvision acquisition 
Hub. images were analyzed using Volocity 3d image analysis software version 5.5 (perkin elmer inc).
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toxin mediated symptoms it is not sufficient 
to prevent outgrowth, sporulation, and 
release of the spores into the environment. 
As current clinical diagnosis is dependent 
upon detection of toxins in fecal samples, 
it is possible that a vaccination strategy 
designed to prevent clinical symptoms 
could lead to an underestimation of the 
extent of colonization in a given target 
population. An ideal vaccine therefore 
should additionally be formulated to 
include bacterial factors that also limit 
colonization. One complication of this 
approach is the lack of information as 
to which bacterial proteins contribute 
to epithelial adhesion and long-term 
persistence. Several surface exposed 
antigens have been proposed including 
SLP, FliD, and cwp84 (Table 1) 34-37. 
The impact of inclusion of these antigens 
in vaccine formulations has been found 
to vary levels of colonization. A further 
complication may be the location and 
nature of the bacterial interaction 
with the epithelial barrier. Evidence 
produced by electron microscopy and 
immunofluorescence suggest that while 
aggregates of bacteria appear associated 
with the epithelial barrier (Fig. 3B) 
bacterial counts (both vegetative and 
spores) recovered from the cecum and 
colon are in significantly higher numbers 
than imaging of the tissue would suggest. 
As a consequence it is difficult to determine 
whether attachment to the epithelial 
barrier is an essential requirement for toxin 
production and disease sequelae. While 
the usefulness of anti-colonization factors 
in acute disease is unclear, the potential to 
eradicate low grade persistent infection is 
attractive. In our studies, animals in the 
acute stage of infection show high levels of 
sporulation with spores detectable in both 
the feces and directly from gut samples 
(approximately 90% of the organisms 
recovered). In contrast, 14 days post 
infection of vaccinated animals or animals 
infected with naturally toxin deficient 
strains of the organism, show a much 
lower proportion of the recovered bacteria 
as spores (less than 50%) (Fig. 3A). In 
these animals, the majority of recovered 
organisms are vegetative cells and this 
may indicate that the organism is retained 
and can continue to persist as a member 
of the normal microbiome. The ability of 
C. difficile to generate biofilms in vitro38,39 
may also play a role in protection from 
subsequent antibiotic treatment and this 
could be prevented if initial colonization 
was limited.
Reducing Clinical Disease and 
Environmental Contamination
One of the most clinically challenging 
problems of C. difficile infection is the 
treatment of patients who initially respond 
to first line antibiotics (vancomycin and 
metronidazole) but suffer a subsequent 
recurrence of symptoms when these drugs 
are withdrawn40. Evidence suggests that 
patients who suffer a relapse either as a 
result of reactivation of a pre-existing 
infection, or infection with a different 
strain, are more likely to suffer subsequent 
episodes of the disease.41 Susceptibility to 
relapse does appear to correlate with long-
term modification of the gut microbiota, 
with microbial diversity a key factor in 
the control of outgrowth and subsequent 
toxin expression and release. This is most 
apparent in the elderly who suffer higher 
incidences of infection than younger 
patients exposed to equivalent antibiotic 
treatment. Further studies within the 
elderly in Ireland have recently shown 
that hospitalized patients show a much 
reduced diversity compared with healthy 
age matched individuals living within 
their own homes42. At this stage it is not 
clear whether bacteriostatic products 
produced by members of the microbiome 
or modification to host proteins, 
including those involved in epithelial 
barrier integrity and immunity, play a 
role in controlling C. difficile outgrowth. 
Combining vaccination with long-
term modifications to the microbiota 
through the use of bacteriotherapy could 
serve to both limit those with disease 
and long-term contamination of the 
environment.
Conclusion and Further 
Questions for Development
Vaccination with recombinant 
fragments from toxin A and toxin B can 
protect hamsters against lethal challenge 
with C. difficile. While the RBD of toxin 
A has been shown in several studies to 
generate strong neutralizing and protective 
antibodies, less is known about the most 
effective antigen from toxin B. We and 
others have proposed that fragments 
encoding the glucosyltransferase activity 
of toxin B provide a vaccine candidate 
that is conserved and that generates strong 
neutralizing activity. The combination of 
these two fragments generates superior 
protection to that observed when the 
RBD region of toxin B is included in the 
formulation. As a consequence, we propose 
that an optimal vaccine against C. difficile 
would include this fragment. Future 
improvements for a vaccine formulation 
should also include the identification of 
anti-colonization factors to limit long-term 
survival of the organism within the host. 
This has implications for reduction in the 
rates of relapse and may help to reduce 
environmental contamination43. While 
vaccination of the elderly can be difficult, 
experience with both pneumococcal 
and influenza vaccines have shown this 
approach has value. Identification of 
strong vaccine candidates that have the 
potential, even in this current form, to 
eliminate or even reduce the debilitating 
and distressing diarrheal symptoms 
associated with this disease is attractive. Its 
use in combination with other antigens or 
with other therapies provides hope in the 
longer term for reduction of environmental 
contamination and source of infection in 
our hospitals and health care institutions.
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